METASTATIC PROSTATE CARCINOMA

This study is testing whether combining two existing drugs works better than using them alone for men with advanced prostate cancer that has specific genetic flaws. It is for men whose cancer has spread and is no longer responding to standard hormone-blocking treatments. The tria…

This study is testing whether combining two drugs, olaparib and cediranib, is more effective than using olaparib alone for men with advanced prostate cancer that has stopped responding to standard hormone therapy and has spread. The trial aims to see if the drug combo can better …

This study is testing a combination of three drugs (apalutamide, abiraterone acetate, and prednisone) for men with advanced prostate cancer that has spread and is still sensitive to hormone-blocking therapy. The goal is to see if this combination, given after standard chemotherap…

This early-stage study is testing a new combination of two drugs, AZD8186 and docetaxel, for patients with advanced solid tumors that have specific genetic changes (PTEN or PIK3CB mutations). The main goals are to find the safest and most effective dose and to understand the side…

This is a small, early-stage safety study testing a combination of two cancer drugs, nivolumab and cabozantinib, in people living with HIV who have advanced solid tumors. The main goal is to see if the two-drug combination is safe and tolerable for this specific patient group. Re…

This early-stage study is testing a new combination of two drugs, DS3201 and ipilimumab, for people with advanced prostate, bladder, or kidney cancer that has spread. The main goals are to find the safest dose and understand the side effects. Researchers hope the drug combo will …

This study is testing a multi-step treatment to control a fast-spreading and hard-to-treat form of prostate cancer. It will involve about 120 men whose cancer has spread and is resistant to standard hormone therapy. The goal is to see if combining chemotherapy, a drug that helps …

This study is testing whether a combination of three drugs can help control prostate cancer that has spread to other parts of the body. Researchers want to see if they can predict which patients will respond best to this treatment by analyzing tumor characteristics. The trial inv…

This study is testing the safety and effectiveness of avelumab, an immunotherapy drug, when given in combination with other immune-boosting drugs and sometimes radiation. It is for patients with advanced solid tumors that have spread and who have run out of standard treatment opt…

This study is testing whether adding an experimental drug called berzosertib to a standard chemotherapy (carboplatin) works better than a different standard combination (docetaxel + carboplatin) for men with advanced prostate cancer that has spread and is no longer responding to …

This study is testing different combinations of approved drugs to find better ways to control advanced prostate cancer that has spread and stopped responding to standard hormone therapy. It involves 196 men and uses a personalized approach: after an initial 8-week treatment, pati…

This study is testing whether men with advanced prostate cancer that has spread can safely take a break from hormone-blocking medications when their cancer responds exceptionally well to treatment. The trial involves 79 men who have been on strong hormone therapy for 18-24 months…

This study is testing the safety and effectiveness of combining two drugs, enzalutamide and cabazitaxel, for men with advanced prostate cancer that has spread and is no longer responding to standard hormone treatments. The goal is to see if using these drugs together can better c…

This study aims to understand if two common prostate cancer drugs, abiraterone and enzalutamide, affect memory, concentration, and other thinking skills. Researchers will use brain scans and cognitive tests to compare 100 men with advanced prostate cancer who are taking these dru…

This study aims to understand how genetic changes in prostate cancer tumors relate to treatment response. Researchers collect tissue, blood, and urine samples from 92 men with advanced prostate cancer before and during standard treatment. By analyzing these samples, they hope to …